44 related articles for article (PubMed ID: 19553031)
1. Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease.
Zimmermann JS; Osieka R; Bruns T; Hollberg H; Wiechmann B; Netzbandt O; Sablotny J; Malade M; Heitz M; Bernhardt F; Tiemann J; Wilkens M; Brüske T; Welker U; Heinemann V; Zimmermann P; de la Maza SF; Pfeiffer D; Tauber PR; Thomas D; Moustakis C
J Contemp Brachytherapy; 2018 Aug; 10(4):297-305. PubMed ID: 30237813
[TBL] [Abstract][Full Text] [Related]
2. Outcome of surgery in locally advanced pT3a prostate cancer.
Milonas D; Baltrimavicius R; Grybas A; Gudinaviciene I; Trumbeckas D; Kincius M; Auskalnis S; Jievaltas M
Cent European J Urol; 2011; 64(4):209-12. PubMed ID: 24578895
[TBL] [Abstract][Full Text] [Related]
3. Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial.
Li HZ; Qi X; Gao XS; Li XM; Qin SB; Li XY; Ma MW; Bai Y; Chen JY; Ren XY; Li XY; Wang D
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):697-705. PubMed ID: 37717784
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of biopsy-based
Repka MC; Sholklapper T; Zwart AL; Danner M; Ayoob M; Yung T; Lei S; Collins BT; Kumar D; Suy S; Hankins RA; Kishan AU; Collins SP
Front Oncol; 2024; 14():1381134. PubMed ID: 38585005
[TBL] [Abstract][Full Text] [Related]
5. Oncologic outcomes of surgery in t3 prostate cancer: experience of a single tertiary center.
Milonas D; Smailyte G; Jievaltas M
Adv Urol; 2012; 2012():164263. PubMed ID: 22216025
[TBL] [Abstract][Full Text] [Related]
6. The long-term outcomes of radical prostatectomy for very high-risk prostate cancer pT3b-T4 N0-1 on definitive histopathology.
Kliment J; Elias B; Baluchova K; Kliment J
Cent European J Urol; 2017; 70(1):13-19. PubMed ID: 28461982
[TBL] [Abstract][Full Text] [Related]
7. A New Pos-SIB-ility for Prostate and Pelvic Nodal Radiation Therapy in High-Risk Localized Prostate Cancer.
Morgan SC; Hu C; Dess RT
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):63-65. PubMed ID: 38049229
[No Abstract] [Full Text] [Related]
8. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
[TBL] [Abstract][Full Text] [Related]
9. Prostate only radiotherapy using external beam radiotherapy: A clinician's perspective.
Lee JW; Chung MJ
World J Clin Cases; 2022 Oct; 10(29):10428-10434. PubMed ID: 36312490
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Toxicity of Whole Pelvic Radiotherapy Versus Prostate-Only Radiotherapy in Localized Prostate Cancer: A Systematic Review and Meta-Analysis.
Wang S; Tang W; Luo H; Jin F; Wang Y
Front Oncol; 2021; 11():796907. PubMed ID: 35155197
[TBL] [Abstract][Full Text] [Related]
11. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
[TBL] [Abstract][Full Text] [Related]
12. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Komori S; Sekiguchi A; Ikeda M; Kurosaka S; Fujita T; Kitano M; Hayakawa K; Iwamura M
J Contemp Brachytherapy; 2016 Apr; 8(2):95-103. PubMed ID: 27257412
[TBL] [Abstract][Full Text] [Related]
14. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS).
Saito S; Ito K; Yorozu A; Aoki M; Koga H; Satoh T; Ohashi T; Shigematsu N; Maruo S; Kikuchi T; Kojima S; Dokiya T; Fukushima M; Yamanaka H
Int J Clin Oncol; 2015 Apr; 20(2):375-85. PubMed ID: 24840041
[TBL] [Abstract][Full Text] [Related]
15. Low rate of lymphedema after extended pelvic lymphadenectomy followed by pelvic irradiation of node-positive prostate cancer.
Rasmusson E; Gunnlaugsson A; Blom R; Björk-Eriksson T; Nilsson P; Ahlgen G; Jönsson C; Johansson K; Kjellén E
Radiat Oncol; 2013 Nov; 8():271. PubMed ID: 24252686
[TBL] [Abstract][Full Text] [Related]
16. Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity.
Kao J; Cesaretti JA; Stone NN; Stock RG
Curr Urol Rep; 2011 Jun; 12(3):237-42. PubMed ID: 21399887
[TBL] [Abstract][Full Text] [Related]
17. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
Bittner N; Merrick GS; Wallner KE; Butler WM; Galbreath R; Adamovich E
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1078-84. PubMed ID: 19553031
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
[TBL] [Abstract][Full Text] [Related]
19. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
